Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

MLA

Young Kwang Chae, et al. “Phase II Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG/NCI Experience: Invasive Mucinous or Non-Mucinous Lepidic Adenocarcinoma of the Lung (Formerly Bronchioloalveolar Carcinoma).” Therapeutic Advances in Medical Oncology, vol. 16, Nov. 2024. EBSCOhost, https://doi.org/10.1177/17588359241293401.

APA

Young Kwang Chae, Megan Othus, Sandip Pravin Patel, David E. Gerber, Tawee Tanvetyanon, Hye Sung Kim, Liam Il-Young Chung, Christine M. McLeod, Gabby Lopez, Helen X. Chen, Elad Sharon, Howard Streicher, Cristopher W. Ryan, Charles D. Blanke, & Razelle Kurzrock. (2024). Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma). Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241293401

Chicago

Young Kwang Chae, Megan Othus, Sandip Pravin Patel, David E. Gerber, Tawee Tanvetyanon, Hye Sung Kim, Liam Il-Young Chung, et al. 2024. “Phase II Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG/NCI Experience: Invasive Mucinous or Non-Mucinous Lepidic Adenocarcinoma of the Lung (Formerly Bronchioloalveolar Carcinoma).” Therapeutic Advances in Medical Oncology 16 (November). doi:10.1177/17588359241293401.